



16 March 2018

ASX Announcement / Media Release

Race increases placement to \$3.639m

16 March 2018 – Race Oncology Limited (ASX: RAC) advises that due to demand for its share placement announced to the market on 12 March 2018, the Company has agreed to accommodate an additional \$480,000 in firm commitments for 1,500,000 shares under the placement. This brings the total funds to be raised under the placement to \$3.639 million.

The additional commitments are in excess of the Company's capacity to issue shares using its 15% placement capacity under ASX Listing Rule 7.1. Accordingly, the Board has agreed to issue the additional shares subject to shareholder approval at a meeting to be convened as soon as practicable.

About Race Oncology (RAC.ASX)

Race Oncology is a specialty pharmaceutical company that listed on the Australian Securities Exchange (ASX) in July 2016. Race's business model is to pursue later-stage drug assets in the cancer field that have been overlooked by big pharma. The company's first asset is Bisantrene, a chemotherapy drug, that was the subject of more than 40 phase II clinical studies during the 1980s and 1990s, then lost in a series of pharmaceutical mergers.

Media contact:

Heidi Cuthbert

+61 411 272 366

E: heidi.cuthbert@multiplier.com.au